. LTX-315 treatment strategy in syngeneic and conditional genetic mouse models.
(A) Schematic of B16F10 melanoma experiments: C57BL/6 wild type mice or Rag2 -/-mice bearing B16F10 melanoma tumor grafts were treated intratumorally (i.t.) with LTX-315 for three consecutive days. Tumor-bearing control mice were left untreated.
(B) Schematic of BP melanoma experiments: Braf V600E /Pten −/− (BP) mice subjected to tamoxifen to produce tumors were treated intratumorally (i.t.) with LTX-315 for three consecutive days or left untreated.
(C) Schematic of KP soft tissue sarcoma experiments: Kras G12D /p53 fl/fl (KP) mice subjected to intramuscular leg injection with Adenovirus expressing Cre recombinase (AdCre) to produce tumors were treated intratumorally (i.t.) with LTX-315 for three consecutive days. Tumorbearing control mice were left untreated.
Figure S2. CD31 staining in untreated and LTX-315-shaped BP and KP tumors.
(A) CD31 staining of tumor sections obtained from Braf V600E /Pten −/− (BP) mice that were either left untreated ("Untreated") or that regrew after LTX-315 treatment ("LTX-315-Shaped"). Both mouse cohorts had similar tumor burden (see also Figure 3A ). Scale bar: 100 µm.
(B) CD31 staining of tumor sections obtained from Kras G12D /p53 fl/fl (KP) mice that were either left untreated ("Untreated") or that regrew after LTX-315 treatment ("LTX-315-Shaped"). Both mouse cohorts had similar tumor burden (see also Figure 3A ). Scale bar: 100 µm.
